GlassScriptPhysician profile
Stephen Robert Vogel
NPI 1366853863
$3,584.35
in general payments reported to CMS, 2019-2025
32 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $967 · 2023: $864 · 2024: $877 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $432.58 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $421.80 | 2021-2025 | Xifaxan |
| Pfizer INC. | $345.26 | 2023-2025 | |
| Corium, LLC | $328.31 | 2022-2025 | Azstarys |
| Amgen INC. | $221.64 | 2022-2025 | Repatha, Otezla, Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $216.96 | 2022 | |
| Lilly USA, LLC | $203.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $177.58 | 2021-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Abbott Laboratories | $171.87 | 2023-2024 | Proclaim, Freestyle Libre 3 |
| Abbvie INC. | $159.62 | 2021-2024 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $151.32 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Ironshore Pharmaceuticals INC. | $120.19 | 2022-2024 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $98.01 | 2021-2024 | Airsupra |
| Sanofi-Aventis U.S. LLC | $93.13 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.79 | 2021-2023 | Trintellix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $44.78 | 2023 | Quviviq |
| Tris Pharma INC | $37.17 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $33.85 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.38 | 2022 | |
| Exact Sciences Corporation | $29.82 | 2024-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $22.24 | 2024 | Yupelri |
| Averitas Pharma INC. | $22.12 | 2023 | Qutenza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.17 | 2022 | |
| Cranial Technologies, INC | $19.94 | 2022 | |
| Axsome Therapeutics, INC. | $19.93 | 2023 | Auvelity |
| Antares Pharma, INC. | $19.14 | 2023 | Tlando, Xyosted, Nocdurna |
| Verona Pharma, INC. | $18.68 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $18.48 | 2025 | Rexulti |
| Dexcom, INC. | $15.98 | 2025 | Dexcom G6 Transmitter |
| Kci USA, INC. | $14.57 | 2022 | |
| Inspire Medical Systems, INC. | $14.04 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Vogel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.